Recent news on Gadoversetamide

Committee for Medicinal Products for Human Use Summary of Positive ...  -  25 May 2007
PharmaLive.com (press release),Gadoversetamide is a chelate containing gadolinium, which is responsible for the contrast enhancement effect in MRI and induces signal intensity changes

EU drug panel doesn't back Amgen's Vectibix for colon cancer  -  25 May 2007
MarketWatchOptimark (gadoversetamide), from Tyco Healthcare Deutschland GmbH, for use in magnetic resonance imaging. Orlistat GSK (orlistat), from Glaxo Group Ltd

FDA Orders Black Box Warning for Gadolinium-Based Contrast Agents  -  May 23, 2007
MedPage Today,Gadodiamide was the most commonly reported agent, when a specific agent was identified, followed by gadopentetate dimeglumine and gadoversetamide.

APS: Contrast Media Used in MRI and Nephrogenic Systemic .........  -  Feb 9, 2007
ANP Pers Support,...gadoversetamide (4,5,8) (OPTIMARK(R)) were used. The physiopathology of this illness. The link between cause and effect cannot be determined for definite.

Contrast Media Used in MRI and Nephrogenic Systemic Fibrosis in ...  -  Feb 9, 2007
netPR.pl (komunikaty prasowe),...was gadodiamide (OMNISCAN(R)), in a smaller number of cases gadopentetate dimeglumine (MAGNEVIST(R)) or gadoversetamide (4,5,8) (OPTIMARK(R)) were used.

Contrast Media Used in MRI and Nephrogenic Systemic Fibrosis in ...  -  Feb 9, 2007
Earthtimes.org...of casesgadopentetate dimeglumine (MAGNEVIST(R)) or gadoversetamide (4,5,8)(OPTIMARK(R)) were used. The physiopathology of this illness remains unclear.

Mallinckrodt signs contracts with Premier  -  18 Jan 2007
St. Louis Business Journal,The company's OptiMARK (gadoversetamide injection) magnetic resonance contrast agent will be available for the first time under contract to Premier members.

MRI Contrast Agents May Pose Risk for Patients With Kidney Disease  -  Jan 16, 2007
Journal of American Medical Association (subscription),...gadopentetate dimeglumine (Magnevist), 2 with gadoversetamide (OptiMARK), 3 with gadodiamide and gadoversetamide, and 3 with unknown contrast agents.

Mallinckrodt Signs New Imaging and Radiopharmaceutical Agreements ...  -  Jan 3, 2007
PR Newswire (press release),Also for the first time, the company's OptiMARK(R) (gadoversetamide injection) magnetic resonance contrast agent will be available under contract to all

FDA Sends Warning Letter to Mallinckrodt Over Exhibit Booth Panels  Oct 19, 2006
...exhibit booth panels (panels) for MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP) and OptiMARK (Gadoversetamide Injection) entitled ... -PharmaLive.com (press release), Tissue characterization of myocardial infarction using T(1rho) ...  Sep 15, 2006
AND METHODS: Eighteen patients with acute myocardial infarction (AMI) were randomly divided into three groups according to the dose of gadoversetamide (0.1, 0.2 ... -HeartZine



Tyco Healthcare / Mallinckrodt and IRadimed Announce North ...  May 11, 2006
Mallinckrodt's dedicated sales specialists are particularly knowledgeable about MRI, given their experience selling OptiMARK® (gadoversetamide injection) and ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional